Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice
Open Access

Multisystem inflammatory syndrome in an adult after SARS-CoV-2 infection

Geneviève Kerkerian and Stephen D. Vaughan
CMAJ June 21, 2021 193 (25) E956-E961; DOI: https://doi.org/10.1503/cmaj.210232
Geneviève Kerkerian
Division of Infectious Diseases, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alta.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen D. Vaughan
Division of Infectious Diseases, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alta.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading
KEY POINTS
  • Multisystem inflammatory syndrome is an uncommon but severe complication primarily described in children and adolescents after infection with SARS-CoV-2; it can also occur in older individuals.

  • After recovery from SARS-CoV-2 infection, clinicians should suspect multisystem inflammatory syndrome in adults when a patient has prolonged fever, with multiorgan involvement.

  • Elevated inflammatory markers support the diagnosis.

  • Prompt initiation of therapy with immunomodulatory treatment can prevent severe outcomes.

A 60-year-old man presented to the emergency department with a 5-day history of mild shortness of breath, profound fatigue, anorexia and fever of up to 40°C. He also reported a lymph node enlargement over the left side of his neck, which had resolved 2 days before presentation. Four weeks earlier, he had tested positive for SARS-CoV-2 infection, confirmed by polymerase chain reaction (PCR) testing. He had no known comorbidities and had not received vaccination against SARS-CoV-2.

The patient’s heart rate was 150 beats/min, with new-onset atrial fibrillation. His blood pressure was 106/67 mm Hg and his oxygen saturation on room air was normal. His respiratory examination showed good air entry bilaterally, without crepitus, crackles or wheezing on auscultation. He had bilateral nonpurulent conjunctivitis (Figure 1A), erythema and enlargement of his tongue (Figure 1B), bilateral pitting edema, and erythema of the distal portion of his toes bilaterally (Figure 1C). Lesions were not associated with any vesicles, erosive features, crusting, fissures, warmth, swelling or tenderness. A chest radiograph showed right lower lobe opacification. An electrocardiogram showed atrial fibrillation with rapid ventricular response, as well as nonspecific diffuse ST-T wave abnormality (Figure 2). Computed tomography (CT) of the patient’s chest with contrast was negative for pulmonary embolism, but showed right heart enlargement and early pulmonary edema.

Figure 1:
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1:

(A) Nonpurulent bilateral conjunctivitis in a 60-year-old man (only right eye shown). (B) Glossitis manifesting as nontender diffuse erythema and symmetric enlargement of the tongue. Small enanthem of the anterior third of the dorsum of the tongue (small erythematous bumps [arrow]) with hyperplastic fungiform and filiform papillae. (C) Left toes showing nonblanching maculopapular erythema. All images were taken before treatment was started.

Figure 2:
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2:

Electrocardiogram showing ventricular rate of 143 beats/min, atrial fibrillation with rapid ventricular response and diffuse nonspecific ST-T wave abnormality.

The patient was admitted and started on empirical piperacillin–tazobactam for possible bacterial pneumonia as a superinfection of his previous SARS-CoV-2 infection. Initial laboratory workup was notable for elevated C-reactive protein, D dimer, ferritin and leukocytosis with neutrophilia (Table 11), indicating acute inflammation. His troponin level was elevated, and he had a substantially elevated pro–brain-type natriuretic peptide level. Blood cultures, urine culture and a respiratory viral panel were drawn and later returned negative. The patient also tested negative for HIV and hepatitis C and was immune to hepatitis B. An autoimmune workup collected before initiation of therapy was negative. COVID-19 immunoglobulin G serology was positive. A transthoracic echocardiogram, done after initiation of corticosteroids, showed normal sinus rhythm and normal right and left ventricular systolic and diastolic function with mild to moderate mitral regurgitation. There were no previous echocardiogram studies with which to compare these findings.

View this table:
  • View inline
  • View popup
Table 1:

Laboratory data for 60-year-old man with multisystem inflammatory syndrome after SARS-CoV-2 infection*

Given the patient’s recent history of SARS-CoV-2 infection, fevers without localizing symptoms, oral mucosal changes, cervical lymphadenopathy, conjunctivitis and lower extremity changes, we suspected inflammatory post–COVID-19 syndrome. The presentation was similar to reported cases of an uncommon but severe complication in children and adolescents infected with SARS-CoV-2, called multisystem inflammatory syndrome in children (MIS-C), as well as to Kawasaki-like illness (Table 22–4). Both the pediatric and adult rheumatology teams involved in the patient’s care agreed that he met the preliminary Centers for Disease Control and Prevention (CDC) criteria for multisystem inflammatory syndrome in adults (MIS-A) and the criteria for complete Kawasaki disease, and he had multiple features consistent with MIS-C.

View this table:
  • View inline
  • View popup
Table 2:

CDC criteria for multisystem inflammatory syndrome in adults and children with SARS-CoV-2 infection and Kawasaki disease2–4

We started the patient on acetylsalicylic acid (ASA) and methylprednisolone and discontinued antibiotics. The next day, he received intravenous (IV) immunoglobulin. Within 24 hours of beginning treatment, he reported substantial improvement in his level of energy, shortness of breath and anorexia, with documented resolution of fever, improved conjunctivitis (Figure 3A), and decreased erythema of his tongue (Figure 3B), as well as reduction in inflammatory markers (Table 1). Repeat electrocardiogram was normal (Figure 4). The patient was discharged home 5 days after admission. Fourteen days after discharge, and again at a 6-week follow-up, he continued to improve clinically and biochemically (Table 1).

Figure 3:
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3:

Near-complete resolution of the patient’s conjunctivitis (A) and improvement in glossitis, and near-complete resolution of enanthem of the tongue (B) on day 1 after initiation of high-dose steroids.

Figure 4:
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4:

Sinus bradycardia of 54 beats/min and otherwise normal electrocardiogram with resolution of atrial fibrillation and ST-T changes prior to discharge.

Discussion

Since the beginning of the SARS-CoV-2 pandemic, new information has been emerging on the trajectory of the disease. Examples of complications include venous thromboembolism, cardiovascular disease, acute kidney or liver injury, neurologic symptoms and post–COVID-19 syndrome.5 Multisystem inflammatory syndrome in children was first described in April 2020 as a hyperinflammatory syndrome with features resembling Kawasaki disease.2,3,6 As of May 3, 2021, 3742 children in the United States had been formally diagnosed with MIS-C according to the criteria outlined in Table 2, with 35 related deaths.7

In October 2020, the CDC published a review of 27 adult cases that fit the description of a multisystem inflammatory syndrome. 4 The preliminary case definition of MIS-A is shown in Table 2, and cases described to date have been in patients younger than 50 years. As we continue to learn about MIS-A, however, it is prudent not to assume any age limitation when considering the diagnosis, as our case suggests.4,8–10

Many questions about MIS-A remain unanswered. Our patient did not present with the more commonly reported symptoms of stroke, shock or cardiac dysfunction requiring management in the intensive care unit.4 This may be explained by our patient having a milder spectrum illness or by the prompt diagnosis and interventions he received. Several features of our patient’s presentation raised early concern for MIS-A or a Kawasaki-like illness. Our patient met the diagnostic criteria for complete Kawasaki disease (5 d of fever and 4 out of 5 clinical features: extremity changes, conjunctivitis, oral changes and cervical lymphadenopathy; our patient did not have a rash) and MIS-C (except for age). However, evidence of recent SARS-CoV-2 infection and the age of the patient made MIS-A more likely as the cause.

The American College of Rheumatology published a review comparing and contrasting features between MIS-C and Kawasaki disease, and it reported that about 25%–50% of patients who fulfilled criteria for MIS-C also met the full diagnostic criteria for Kawasaki disease.11 Two differences between the conditions were ethnic distribution (highest among people of Japanese descent in patients with Kawasaki disease) and age distribution (usually younger than 5 yr for Kawasaki disease, and a broader range, from 3 months to 21 yr, for MIS-C).2,11,12

Standardized treatment for MIS-A is yet to be established. Our patient improved with 3 days of methylprednisolone 125 mg/d, then an oral prednisone taper of 50 mg/d for 3 days, followed by a tapering dose decreasing by 10 mg/d every 3 days until he was weaned off steroids (for a total oral course of 15 d). He received IV immunoglobulin 1 g/kg/d for 2 days and oral ASA 325 mg/d until clinical resolution, as evidenced by absence of fevers and normal C-reactive protein. This treatment was based on expert opinion and up-to-date evidence on Kawasaki disease and MIS-C.2,6,8,11–13 The American College of Rheumatology recommends a step-wise approach to immunomodulatory treatment in MIS-C with IV immunoglobulin or glucocorticoids considered as first-tier agents,11 and the American Heart Association recommends high-dose immunoglobulin (2 g/kg) as a single IV dose for treatment of Kawasaki disease.2 Although the patient did not have clinically significant thrombocytosis, we prescribed a short course of high-dose ASA to prevent thrombosis and coronary artery aneurysms.11

The optimal follow-up for MIS-A is currently unknown, but experts support monitoring for coronary artery dilatation and aneurysm, as with MIS-C-or Kawasaki-like illness.2,11 Unlike in children, for whom echocardiography is the imaging choice for coronary artery diameter, the visualization of coronary arteries becomes progressively more difficult as body size increases, making CT coronary angiography preferred for surveillance in adults.2 Our patient’s coronary angiogram showed triple-vessel coronary artery disease without clinically important stenosis and no coronary aneurysms or findings suggestive of coronary artery vasculitis. At time of writing, a repeat CT to visualize coronary artery calibre is still pending for 6 months after discharge.

Unlike for MIS-C, there is currently no requirement to report cases of MIS-A to provincial or state authorities, but this should be encouraged to facilitate research and improve patient outcomes.6

The section Cases presents brief case reports that convey clear, practical lessons. Preference is given to common presentations of important rare conditions, and important unusual presentations of common problems. Articles start with a case presentation (500 words maximum), and a discussion of the underlying condition follows (1000 words maximum). Visual elements (e.g., tables of the differential diagnosis, clinical features or diagnostic approach) are encouraged. Consent from patients for publication of their story is a necessity. See information for authors at www.cmaj.ca.

Acknowledgements

The authors acknowledge Drs. Glen Hazlewood, Heinrike Schmeling and Kevin Fonseca for their expert opinion in the management of this case.

Footnotes

  • Competing interests: None declared.

  • This article has been peer reviewed.

  • The authors have obtained patient consent.

  • Contributors: Both authors contributed to the conception and design of the work, drafted the manuscript, revised it critically for important intellectual content, gave final approval of the version to be published and agreed to be accountable for all aspects of the work.

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/

References

  1. ↵
    Ontario Agency for Health Protection and Promotion (Public Health Ontario). An overview of cycle threshold values and their role in SARS-CoV-2 real-time PCR test interpretation. Toronto: Queen’s Printer for Ontario; 2020. Available: www.publichealthontario.ca/-/media/documents/ncov/main/2020/09/cycle-threshold-values-sars-cov2-pcr.pdf?la=en (accessed 2021 May 11).
  2. ↵
    1. McCrindle BW,
    2. Rowley AH,
    3. Newburger JW,
    4. et al.
    American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Epidemiology and Prevention. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation 2017;135:e927–99.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    National Center for Immunization and Respiratory Diseases (NCIRD). Information for healthcare providers about multisystem inflammatory syndrome in children (MIS-C). Atlanta: Centers for Disease Control and Prevention; reviewed 2021 Feb. 17. Available: https://www.cdc.gov/mis-c/hcp/#:~:text=Case%20Definition%20for%20MIS%2DC&text=No%20alternative%20plausible%20diagnoses%3B%20AND,to%20the%20onset%20of%20symptoms (accessed 2021 Jan. 13).
  4. ↵
    1. Morris SB,
    2. Schwartz NG,
    3. Patel P,
    4. et al
    . Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 Infection — United Kingdom and United States, March–August 2020. MMWR Morb Mortal Wkly Rep 2020;69: 1450–6.
    OpenUrlCrossRefPubMed
  5. ↵
    Complications. In: BMJ Best Practice: Coronavirus diseases 2019 (COVID-19). London (UK): BMJ; 2021. Available: bestpractice.bmj.com/topics/en-us/3000168/pdf/3000168/Coronavirus%20disease%202019%20%28COVID-19%29.pdf (accessed 2021 Jan. 11).
  6. ↵
    1. Cheung EW,
    2. Zachariah P,
    3. Gorelik M,
    4. et al
    . Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in New York City. JAMA 2020;324:294–6.
    OpenUrlCrossRefPubMed
  7. ↵
    National Center for Immunization and Respiratory Diseases (NCIRD). Health department-reported cases of multisystem inflammatory syndrome in children (MIS-C) in the United States. Atlanta: Centers for Disease Control and Prevention; reviewed 2021 May 11. Available: https://www.cdc.gov/mis-c/cases/index.html (accessed 2021 Jan. 10).
  8. ↵
    1. Kofman AD,
    2. Sizemore EK,
    3. Detelich JF,
    4. et al
    . A young adult with COVID-19 and multisystem inflammatory syndrome in children (MIS-C)-like illness: a case report. BMC Infect Dis 2020;20:716.
    OpenUrlCrossRefPubMed
    1. Shaigany S,
    2. Gnirke M,
    3. Guttmann A,
    4. et al
    . An adult with Kawasaki-like multisystem inflammatory syndrome associated with COVID-19. Lancet 2020;396:e8–10.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Ahsan T,
    2. Rani B
    . A case of multisystem inflammatory syndrome post-COVID-19 infection in an adult. Cureus 2020;12:e11961.
    OpenUrl
  10. ↵
    1. Henderson LA,
    2. Canna SW,
    3. Friedman KG,
    4. et al
    . American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 1. Arthritis Rheumatol 2020;72:1791–805.
    OpenUrl
  11. ↵
    1. Gomard-Mennesson E,
    2. Landron C,
    3. Dauphin C,
    4. et al
    . Kawasaki disease in adults: report of 10 cases. Medicine (Baltimore) 2010;89:149–58.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Tam H,
    2. El Tal T,
    3. Go E,
    4. et al
    . Pediatric inflammatory multisystem syndrome temporally associated with COVID-19: a spectrum of diseases with many names. CMAJ 2020;192:E1093–6.
    OpenUrlFREE Full Text
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 193 (25)
CMAJ
Vol. 193, Issue 25
21 Jun 2021
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Multisystem inflammatory syndrome in an adult after SARS-CoV-2 infection
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Multisystem inflammatory syndrome in an adult after SARS-CoV-2 infection
Geneviève Kerkerian, Stephen D. Vaughan
CMAJ Jun 2021, 193 (25) E956-E961; DOI: 10.1503/cmaj.210232

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Multisystem inflammatory syndrome in an adult after SARS-CoV-2 infection
Geneviève Kerkerian, Stephen D. Vaughan
CMAJ Jun 2021, 193 (25) E956-E961; DOI: 10.1503/cmaj.210232
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • Syndrome inflammatoire multisystémique chez un adulte après une infection par le SRAS-CoV-2
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Bedbugs
  • Epinephrine in anaphylaxis
  • Achalasia with megaesophagus
Show more Practice

Similar Articles

Collections

  • Article Types
    • Cases
  • Topics
    • Family medicine, general practice, primary care
    • Infectious diseases: COVID-19
    • Internal medicine
    • Rheumatology

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

CMA Civility, Accessibility, Privacy

 

Powered by HighWire